A beta-Degrading Proteases: Therapeutic Potential in Alzheimer Disease

作者：Leissring Malcolm A^*

来源：CNS Drugs, 2016, 30(8): 667-675.

DOI：10.1007/s40263-016-0364-1

The amyloid beta-protein (A beta) plays an indispensable role in the pathogenesis of Alzheimer disease (AD). A beta is subject to proteolytic degradation by a diverse array of peptidases and proteinases, known collectively as A beta-degrading proteases (A beta DPs). A growing number of A beta DPs have been identified that impact A beta powerfully and in a surprising variety of ways. As such, A beta DPs hold considerable therapeutic potential for the treatment and/or prevention of AD. Here, we critically review the relative merits of therapeutic strategies targeting A beta DPs compared with current A beta-lowering strategies focused on immunotherapies and pharmacological modulation of A beta-producing enzymes. Several innovative advances have increased considerably the feasibility of delivering A beta DPs to the brain or enhancing their activity in a non-invasive manner. We argue that therapies targeting A beta DPs offer numerous potential advantages that should be explored through continued research into this promising field.

• 出版日期2016-8